Alligator Bioscience AB at Biostock Life Science Summit (Virtual) Transcript
-- where our next presenter is Per Norlen, CEO of Alligator Bioscience. Welcome, Per.
Thank you. All right. We're ready to go.
Go ahead.
So thank you so much. Alligator is a clinical stage public immuno-oncology biotech company. And I would like straight to the company highlights. So Alligator has generated five clinical stage programs built on our own technology platforms. We have a very strong innovation track record, and we brought them all the way from ID to clinical stage.
Today, we focus on two of these assets, lead asset assets that are moving into clinical Phase 2. And those two assets are optimized for best and first-in-class profile, and which is supported by a very strong preclinical and clinical package. We have also studies coming up already in 2021, and I will come back to this soon.
Also
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |